3 Reasons Why Moderna Stock Presents Exciting Investment Opportunities
Reasons to Buy Moderna Stock:
The company can still deliver excellent returns. The past four years have been a roller-coaster ride for Moderna (NASDAQ: MRNA). The mRNA-focused vaccine maker rose to prominence following a successful attempt at developing a coronavirus vaccine.
Gaining market share:
Though the coronavirus vaccine market is no longer as lucrative as it once was, it isn't going away completely. Moderna is improving its position in the coronavirus vaccine space and gaining ground against its biggest rival, Pfizer.
A potential catalyst:
Moderna is close to launching a non-coronavirus product, the RSV vaccine, which could contribute significantly to its top line and reduce reliance on its coronavirus franchise.
A deep pipeline:
Moderna has numerous products in its late-stage pipeline, including a vaccine for cytomegalovirus and a COVID-influenza combination vaccine. The biotech's collaboration with Merck on a cancer vaccine also shows significant potential for future growth.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.